Graham Kelly seeks cash for new Australia oncology biotech

Spotlight
Stock
A picture of Graham Kelly from the shoulders up
Graham Kelly

Former Novogen ($NVGN) CEO Graham Kelly is raising money for a new Australian biotech called Noxopharm that is said to be ready with a Phase I oncology candidate, NOX66 (idronoxil), for later this year that also follows a path of a drug touted by his former firm to overcome chemotherapy resistance.

Kelly hopes to get up and running with AU$6 million via an initial public offering on the Australian Stock Exchange (ASX) of 30 million shares at $0.20 each, the company said in a statement.

"NOX66 is an innovative dosage form of the drug candidate, idronoxil. Idronoxil overturns drug-resistance mechanisms, but has failed in clinical studies to reproduce the potency observed in the laboratory," the company said in the release.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"Noxopharm believes it understands the cause of that failure and what is required to overcome it. NOX66 is the result of that belief."

The clinical trial planned for the European country of Georgia could set the stage for an immediate Phase IIa if successful, the company said.

In July of last year, Kelly left Nasdaq- and ASX-listed Novogen in an abrupt manner following what the company said was a promising in vivo proof of concept study for anti-tropomyosin drug candidate Anisina, CHLA20, in combination with vincristine in the U.S., a candidate also aimed at increasing the effectiveness of chemotherapy.

- here's the release

Related Articles:
Abrupt departure of Novogen CEO followed upbeat Anisina presentation

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.